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In preclinical studies, BNP7787 (disodium 2,20-dithio-bis-ethane sulphonate), the disulphide form of mesna, has demonstrated
selective protection against cisplatin-induced nephrotoxicity due to conversion into mesna inactivating toxic platinum species. Mesna
(sodium 2-mercapto ethane sulphonate), however, can affect the antitumour activity of cisplatin, while BNP7787 does not interfere
with the antitumour activity. To understand the difference in interference with cisplatin-induced antitumour activity between
BNP7787 and mesna as well to characterise the selective nephroprotection by BNP7787, the pharmacokinetics of BNP7787 and
mesna, each given i.v. 1000mgkg
 1, were determined in plasma, kidney, liver, red blood cells (RBC), skeletal muscle and tumour of
Fischer rats bearing subcutaneously implanted WARD colon tumours. The following results were obtained: (1) high concentrations of
BNP7787 and mesna were observed in the plasma and kidney after administration of BNP7787 or mesna, except for mesna in
plasma after BNP7787 administration; (2) in all other sampled compartments, the AUC values of both compounds were at least 5.5-
fold lower than the corresponding values in kidney; (3) the AUC of mesna in plasma after mesna administration was comparable to
the AUC of mesna in kidney after a dose of BNP7787 that can completely prevent cisplatin-induced nephrotoxicity in rats; (4) the
AUC of mesna in plasma was five-fold higher relative to the AUC of mesna following BNP7787 administration (Po0.01). In
conclusion, the five-fold higher AUC of mesna in plasma after mesna administration and the fact that mesna is more reactive with
(hydrated) cisplatin than its disulphide form BNP7787 represent a plausible explanation as to why mesna administration can reduce
the antitumour activity of cisplatin. After BNP7787 administration, the distribution of BNP7787 and mesna was restricted to the
kidney, which confirmed the selective protection of the kidney by BNP7787.
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Cisplatin (cis-diamminedichloroplatinum [II], CDDP) is a highly
active cytotoxic agent that is widely used for the treatment of solid
tumours, including those of the lung, head and neck, ovary and
testis. Besides its antitumour activity, cisplatin can cause serious
side effects, such as dose-limiting nephrotoxicity and neurotoxi-
city. Several chemoprotectors have been studied with a view to
prevent or reduce cisplatin-induced nephrotoxicity. An optimal
chemoprotector should meet the following requirements: it
should protect against the nephrotoxicity and preferably also
against other common and serious cisplatin-induced side effects;
it should not reduce the antitumour activity of cisplatin and
should not be toxic by itself (Hausheer et al, 1998). Various
protective compounds, such as thiosulphate (Wagner et al,
1988), diethyldithiocarbamate (Berry et al, 1990) and amifostine
(Hospers et al, 1999) have failed to meet these requirements due to
side effects or interference with the antitumour activity of
cisplatin.
Mesna (sodium 2-mercaptoethane sulphonate), which is used
clinically to prevent oxazaphosphorine-induced haemorrhagic
cystitis (Links and Lewis, 1999), has been investigated as a
potential chemoprotector against cisplatin-induced nephrotoxicity
(Kempf et al, 1985). Studies in tumour-bearing rats and nude mice,
however, have demonstrated that mesna administration preceding
cisplatin can reduce the number of complete and partial tumour
remissions (Hausheer et al, 1998) and reduce the specific growth
delay (Boven et al, 2002) in comparison with data obtained with
cisplatin alone. In contrast, administration of the disulphide of
mesna, BNP7787 (disodium 2,20-dithio-bis-ethane sulphonate), in
the same animal tumour models (Hausheer et al, 1998; Boven et al,
2002), did not reduce the antitumour activity of cisplatin. A likely
explanation for the difference in interference with cisplatin-
induced antitumour activity is a difference in the reactivity of
BNP7787 and mesna with cisplatin in combination with a
difference in concentrations between BNP7787 and mesna in
plasma and tumour levels after administration of BNP7787 or
mesna. After mesna administration, the plasma levels of the thiol
compound mesna, which is approximately two-fold more reactive
with (hydrated) cisplatin than BNP7787 (Leeuwenkamp et al, 1991;
Verschraagen et al, 2003a), might be higher than after BNP7787
administration, which will result in inactivation of cisplatin in
plasma before it can reach the tumour tissue. In addition, mesna
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sconcentrations after mesna in tumour tissue might be higher than
after BNP7787 administration, resulting in local inactivation of
cisplatin.
It has been previously demonstrated that BNP7787, which was
nontoxic after i.v. administration in high doses (i.e. 2000mgkg
 1
in dogs and 4000mgkg
 1 in rats), completely protected against
cisplatin-induced nephrotoxicity in rats and dogs based on plasma
creatinine and BUN values, and more definitively by renal
histopathological examinations, which were indistinguishable from
normal healthy controls (Hausheer et al, 1998). The selectivity of
BNP7787 is probably based on the preferential uptake of BNP7787
in the kidneys and the subsequent local formation of its metabolite
mesna. In vitro studies using isolated cells have shown that the
hydrophilic compound BNP7787 was preferentially taken up in
intestinal and renal epithelial cells via facilitated transport
(Ormstad and Uehara, 1982; Ormstad et al, 1983; Brock et al,
1984; Ormstad and Ohno, 1984). In these cells, BNP7787 was
reduced to mesna (Ormstad and Uehara, 1982; Ormstad, 1983).
The high concentrations of mesna in the kidney can locally
inactivate (hydrated) cisplatin by forming nontoxic platinum
complexes and can additionally protect against cisplatin-induced
toxicity by acting as an antioxidant (Bast et al, 1987; Mashiach et al,
2001) (Figure 1).
The first aim of this study was to find a possible explanation for
the difference in interference with the cisplatin antitumour activity
between mesna and BNP7787 administration. Therefore, the
concentrations of BNP7787 and mesna were determined in the
plasma and tumour tissue of WARD tumour-bearing Fischer rats
after intravenous bolus injection of BNP7787 or mesna. Our
second aim was to verify the selective protecting properties of
BNP7787. Therefore, the concentrations and distribution of
BNP7787 and mesna were measured in plasma, tumour as well
as in kidney, red blood cells (RBC), liver and skeletal muscle. The
liver was included, because it is an important excretion organ
besides the kidney. Furthermore, the RBCs were included to
determine whether they could act as a drug reservoir, whereas the
skeletal muscle was included to investigate whether BNP7787 could
be taken up in ‘normal’ (nonexcreting) tissue.
MATERIALS AND METHODS
Drug solutions
Drug solutions were prepared immediately prior to administration.
BNP7787 was supplied by BioNumerik Pharmaceuticals (San
Antonio, TX, USA) and was dissolved in water for injection at a
concentration of 200mgml
 1. Mesna was obtained from Sigma (St
Louis, MO, USA) and was also dissolved in water for injection to
obtain a concentration of 200mgml
 1.
Animals
The protocol was approved by the ethics committee for animal
experiments of the Vrije Universiteit medical center in Amster-
dam, The Netherlands. This committee strictly adheres to the
standards required by the UKCCCR for the welfare of animals in
neoplasia (Workman et al, 1998). Female Fischer rats (144–171g)
were obtained from Harlan (Indianapolis, USA) and were
implanted subcutaneously in both flanks with fragments (2–
3mm diameter) of the WARD colorectal tumour (Cao et al, 1994).
The pharmacokinetic study started at the time the tumours had
reached a mean size of approximately 600mm
3 (range 250–
900mm
3).
Sampling
Tumour-bearing rats were treated with 1000mgkg
 1 BNP7787 i.v.
or 1000mgkg
 1 mesna i.v. injected in the tail vein. Approximately
5min before sample collection, the rats were anaesthetised by i.p.
injection with 0.1ml of a mixture of 75mgml
 1 ketamine plus
5mgml
 1 xylazine per 100g weight. Blood was obtained by heart
puncture at 0, 5, 15, 30, 45, 60, 90 and 150min after i.v.
administration of BNP7787 or mesna. Thereafter, the kidney, liver
and tumour were removed by surgical dissection. In addition, at
time points 0 and 30min, skeletal muscle attached to the thighbone
was also collected. At each time point three rats were killed. Due to
the relatively large variation in mesna and BNP7787 plasma
concentration at t¼15min after BNP7787 and mesna administra-
tion and t¼45min after mesna administration, an extra rat was
included at these time points.
Sample pretreatment
Immediately after collection, the blood samples, which were
collected in cooled EDTA-containing tubes (potassium-EDTA
1.6mg EDTAml
 1 blood; Sarstedt, Germany), were centrifuged
at 41C for 10min at 4000g. Plasma was separated and immediately
deproteinised by adding one volume of sulphuric acid (0.33 M) and
one volume of sodium hexametaphosphate (5g/100ml). After
vortexing and centrifugation for 2min at 12000g, the supernatant
was stored in aliquots at  801C until analysis. One volume of RBCs
was washed with 1 volume of cold phosphate-buffered saline (PBS)
of pH 7.4 containing sodium phosphate (10mM) and NaCl
(140mM; Hospital Pharmacy, VUmc, Amsterdam, The Nether-
lands). This mixture was centrifuged for 2min, 12000g at 41C.
After removing the PBS, the remaining RBCs were stored in liquid
nitrogen until further processing.
The kidney, liver, tumour and skeletal muscle were washed with
cold PBS before storage in liquid nitrogen. After collection of all
the samples at the different time points, tissue homogenates of
kidney, liver, tumour and skeletal muscle were prepared by
pulverisation using a Braun Micro-dismembrator (Salm and Kipp;
Breukelen, The Netherlands) according to the method described by
Peters et al (1986). An appropriate volume of aqueous EDTA
(1gl
 1) was added to the RBC and tissue homogenates to obtain a
concentration of 100mg tissue (wet weight) per ml. After
sonification (10min) and vortexing (10min), the samples were
subsequently deproteinised by adding 1 volume of cold sulphuric
acid (0.33 M) and 1 volume of cold sodium hexametaphosphate
(5g/100ml). After thorough vortexing and centrifugation (2min at
8500g at 41C), the supernatants were stored in aliquots at  801
until analysis.
O O
S O O CH2CH2 S SC H 2CH2
O
OC H 2CH2 SH
Pt
H3N
H3N Cl
OH2
Cl
H3N
Pt
H3N
SCH2CH2SO3 
− Cl
Cl
H3N
Pt
H3N
OH
Cl
H3N
Pt
H3N
 S
O − Na+ O −  Na+
BNP7787
S
O −  Na+
Mesna
Reduction
Cisplatin
Monoaqua cisplatin
+
Mesna-platinum adduct
Monohydroxo cisplatin
Oxidation
Figure 1 Proposed detoxification mechanism of BNP7787 in the kidney.
After administration, BNP7787 will be converted into its metabolite mesna
(and vice versa) in kidney, which can then react with cisplatin species to
form inactive mesna–platinum adducts.
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sSample analysis
BNP7787 and mesna concentrations were determined selectively in
one run using micro-HPLC with a dual electrochemical detector
(dual ECD) (Verschraagen et al, 2003b). Briefly, citrate-NaOH
buffer (40ml of a mixture of 1ml 5.0 M sodium hydroxide and 4ml
0.5 M tri-sodium citrate buffer, pH 3.0) was added to 200mlo f
deproteinised plasma, RBC or tissue sample, and the sample was
injected into the micro-HPLC system which consisted of a
Phenomenex C18 guard column (10mm, 4 2.0mm) and a
Phenomenex Prodigy C18 ODS-3 column (5mm, 100 1.0mm;
Bester, Amstelveen, The Netherlands). The mobile phase consisted
of tri-sodium citrate dihydrate (0.15 M), tetrabutyl ammonium
dihydrogen phosphate (TBAP) (0.05 or 0.1mM) and cysteamine
(0.1mM), and was adjusted to pH 3.5 with 85% o-phosphoric acid.
The flow rate was 0.05mlmin
 1 and column temperature was
361C. After separation of BNP7787 and mesna by micro-HPLC,
both compounds were detected with a dual ECD (Decade with
Twin option set at 361C; Antec Leyden, Zoeterwoude, The
Netherlands). At the first electrode, the disulphide BNP7787 was
reduced to mesna by a reactor cell with a glassy carbon-working
electrode ( 1.6V vs Hy-REF). At the second electrode, which
consisted of a gold wall-jet electrode, the mesna generated from
BNP7787 and the mesna already present in the samples were
detected (þ0.85V vs Ag/AgCl).
The assays for BNP7787 and mesna in plasma were linear over
the range of 15–1200 and 3–120mM, respectively. Quality control
verification samples of BNP7787 and mesna in plasma were used at
three different concentrations, that is, for BNP7787 45, 225 and
900mM and for mesna 4.5, 22.5 and 90mM. The RBC and tissue
samples from the rats were measured with a calibration curve
produced in tissue homogenate from pig kidney. In tissue, the
dynamic range was 20–2000nmolg for BNP7787 and mesna.
Quality control samples of both compounds in tissue were used at
three different concentrations, that is, 50, 250 and 1250nmolg
 1
for BNP7787 as well as for mesna. The lower limit of quantification
of both compounds was 3mM in plasma and 20nmolg
 1 in tissue.
The within- and between-day accuracy and precision for plasma
and tissue were within 14 and 7%, respectively.
Pharmacokinetic and statistical analysis
Semilogarithmic concentration–time curves of BNP7787 and
mesna were obtained by plotting the mean concentration (C ¯i)o f
each drug vs time (ti). Areas under the concentration–time curves
(AUCs) were calculated over 5–150min after administration of the
drugs or up to the time of the last measurable concentration
(4LLQ) before 150min after administration. AUCs were calcu-
lated by the trapezoidal rule:
AUC ¼
X n
i¼1
ðWi     C CiÞ
with
Wi ¼
0:5ðt2   t1Þ fori ¼ 1
0:5ðtiþ1   ti 1Þ fori ¼ 2;...;n   1
0:5ðtn   tn 1Þ fori ¼ n
8
<
:
The standard errors (S.E.) of the AUC values were calculated by:
s:e: ¼
ﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃﬃ
X n
i¼1
ðW2
i  ð s:d:2
i=niÞ
 ! v u u t :
in which s.d.i is the standard deviation of the concentrations of the
drug at each time point i and n is the number of animals at each
time point i.
The z-test was used for the statistical evaluation of the results, as
suggested by Bailer for destructive measurement techniques
(Bailer, 1988). Since several hypotheses were tested, the P-values
were adjusted for multiple pairwise testing using the Bonferroni
formula: adjusted P¼k*P, in which k represents the number of
comparison tests (Altman, 1991). P-values less than 0.05 were
considered statistically significant.
RESULTS
Mesna administration
Following the i.v. administration of 1000mgkg
 1 mesna, the
highest concentrations of mesna were observed at 5 and 30min
after administration in all sampled compartments (Figure 2a
and b). After 30min, the concentrations of mesna gradually
decreased. The highest concentrations of the metabolite BNP7787
were observed at 5 and 30min following administration, indicating
that the generation of BNP7787 from mesna was relatively rapid.
Mesna and BNP7787 were detectable for at least 150min in kidney,
plasma and tumour, and mesna was also detectable in RBC and
liver during this time period.
Comparison of the concentrations of the parent drug mesna
with the metabolite BNP7787 revealed that the concentrations of
mesna were much higher than the concentrations of BNP7787 in all
sampled compartments. This was reflected by the AUCs of mesna,
which were at least seven-fold higher than the AUCs of BNP7787 in
plasma and all tissues sampled.
Comparison of the concentrations of mesna and BNP7787
between the sampled compartments showed that the concentra-
tions of both compounds were the highest in kidney, followed by
plasma4tumour4RBC4liver (Figure 2a and b). The kidney–
plasma AUC ratios of mesna and BNP7787 were 1.7 and 2.1,
respectively. In all other tissue compartments, the tissue–plasma
AUC ratios of mesna as well as of BNP7787 were lower than 0.3. At
30min after mesna administration, the mean concentrations
(7s.d.) of mesna and BNP7787 in skeletal muscle were
665.17209.1 and 30.3717.6nmolg
 1, respectively. These concen-
trations were lower than any concentration of both compounds
measured at that time point in plasma or the other sampled tissues.
BNP7787 administration
Semilogarithmic mean concentration–time curves of BNP7787 and
generated mesna after the i.v. administration of 1000mgkg
 1
BNP7787 are shown in Figure 3a and b. The highest concentrations
of BNP7787 were observed in all compartments at 5min after
administration. High peak levels of the metabolite mesna were
maintained between 5 and 30min after administration of BNP7787.
Only in the liver the mesna concentrations decreased immediately
after the maximal concentration was observed at 5min after
administration. BNP7787 could be detected for 90min in the
plasma and kidney, 45min in tumour and only 30min in RBC and
liver. Mesna could be detected for at least 150min in kidney and
tumour, whereas in plasma, liver and RBC mesna could be
detected up to 90min after BNP7787 administration.
In plasma, the concentrations of the parent drug BNP7787 were
higher than the concentrations of its metabolite mesna, as reflected
by the AUC of BNP7787, which was almost two-fold higher than
the AUC of mesna. In contrast, the AUCs of BNP7787 in the
kidney, RBC, liver and tumour were, respectively, 2.7-, 11.4-, 39.8-
and 5.1-fold lower than the AUC of mesna in these tissues.
The highest BNP7787 concentrations were obtained in plasma
and kidney, whereas the concentrations of BNP7787 in liver, RBC
and tumour were substantially lower (Figure 3a and b). This was
also reflected by the tissue–plasma AUC ratios, which were 0.9 in
kidney, 0.08 in tumour and 0.01 in RBC and liver. The highest
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administration were reached in the kidney and were much higher
than the concentrations in plasma, as reflected by the kidney–
plasma AUC ratio of 4.5. Mesna concentrations observed in the
liver, RBC and tumour were lower than those in plasma (i.e.
tissue–plasma AUC ratios of 0.5, 0.1 and 0.7, respectively). At
30min after administration of BNP7787, the mean concentrations
(7s.d.) of BNP7787 and mesna in skeletal muscle were 36.9726.0
and 355.17113.0nmolg
 1, respectively, which were lower than the
concentrations observed in any of the sampled compartments at
the same time.
BNP7787 vs mesna administration
For reasons of comparison, the AUC values of BNP7787 after
BNP7787 and mesna administration are depicted in Figure 4a,
while those of (generated) mesna are shown in Figure 4b.
In plasma, the AUC of BNP7787 was more than three-fold higher
after BNP7787 administration than after mesna administration
(Po0.01, Figure 4a). A smaller, but not significant difference was
observed in kidney. In contrast, a six-fold lower concentration of
BNP7787 was measured in RBC after BNP7787 administration
(Po0.01). The AUC values of BNP7787 in the other compartments
(i.e. liver and tumour) were not significantly different following the
administration of BNP7787 or mesna.
In plasma, the AUC of mesna was five-fold lower following
BNP7787 administration than after mesna administration
(Po0.01, Figure 4b). In kidney and RBC, a respectively 1.9-fold
and 6.2-fold lower AUC of mesna was observed after BNP7787 than
after mesna administration (Po0.01). Of interest, the AUC of
mesna in the tumour was 2.1-fold lower following BNP7787
administration relative to mesna administration, although this was
not statistically significant. In the liver, the absolute AUC values of
mesna were similar after BNP7787 and mesna administration.
DISCUSSION
Currently, BNP7787 is undergoing clinical development to study
its potential as a chemoprotector against cisplatin-induced
nephrotoxicity, as well as platinum- and taxane-induced neuro-
toxicity (Hausheer et al, 1998, 1999; Cavalletti et al, 1999; Boven
et al, 2002). In the kidneys, BNP7787 is postulated to undergo
selective conversion into mesna, which can locally detoxify
cisplatin. Studies in tumour-bearing rats (Hausheer et al, 1998)
have confirmed the selectivity of BNP7787 administration that
resulted in complete protection against cisplatin-induced nephro-
toxicity, as documented by histopathological examination, with
full preservation of the antitumour activity of cisplatin. In contrast,
reduction of the antitumour activity of cisplatin was observed in
tumour-bearing rats and nude mice receiving mesna (Hausheer
et al, 1998; Boven et al, 2002). The results in this study showed that
high concentrations of BNP7787 and mesna were observed in the
plasma and kidney of WARD tumour-bearing rats receiving either
BNP7787 or mesna. In all other tissue-sampled compartments, the
AUC values of BNP7787 and mesna were at least 5.5-fold lower
than the corresponding values in kidney. After mesna adminis-
tration, the plasma concentrations of mesna were substantially
higher than those after BNP7787 administration and were
comparable to the concentrations of mesna obtained in the kidney
after BNP7787 administration.
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Figure 2 Semilogarithmic mean concentration (7s.d.)–time curves of
BNP7787 (A) and mesna (B) in the kidney (K), plasma (J), tumour (’),
RBC (n) and liver (m), obtained after administration of 1000mgkg
 1 i.v.
mesna in Fischer rats.
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Figure 3 Semilogarithmic mean concentration (7s.d.)–time curves of
BNP7787 (A) and mesna (B) in the kidney (K), plasma (J), tumour (’),
RBC (n) and liver (m), obtained after administration of 1000mgkg
 1 i.v.
BNP7787 in Fischer rats.
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sFor pharmacokinetic comparison of the various samples
described herein, AUCs to infinity are preferred. However, due
to the large variations in some C ¯i values, it was not possible to
perform reliable AUC extrapolations to infinity for all tissues.
Therefore, AUCs were calculated from 5min after drug adminis-
tration up to the last measurable concentration or to the last
sampling time, that is, 150min (AUC
5 t). The quality of the latter
approach is illustrated by calculating the AUC
5 N values of the
smooth concentration–time curves. In these cases, AUC
5 N
values were less than 13% higher than the corresponding AUC
5 t
values. AUC
5 N values of BNP7787 in the liver after mesna or
BNP7787 administration and in RBC after BNP7787 administration
differed much more from the calculated AUC
5 t values. This large
variation was due to the limited number of time points, with
concentrations of BNP7787 above the lower limit of quantification
in these compartments. In addition, by using AUC
5 t, it is possible
to calculate an s.d. for AUC
5 t, which is not possible for AUC
5 N.
The aforementioned data show that the obtained AUC
5 t values
are reliable values, which we can use for comparative pharmaco-
kinetics.
Mesna has been shown to attenuate the antitumour activity of
cisplatin, whereas administration of its disulphide BNP7787 did
not (Hausheer et al, 1998; Boven et al, 2002). This distinction
between the two compounds can possibly be explained by the
higher plasma and tumour levels of mesna after administration of
mesna, since mesna is more reactive with (hydrated) cisplatin than
its disulphide BNP7787 (Leeuwenkamp et al, 1991; Verschraagen
et al, 2003a). High concentrations of mesna were observed in
plasma after administration of 1000mgkg
 1 mesna i.v. The AUC
of mesna in plasma after mesna was substantially higher (five-fold)
than the AUC of mesna after BNP7787 administration (Po0.01). In
the tumour, the concentrations of mesna after mesna administra-
tion were also higher than after BNP7787 administration. The two-
fold higher AUC value of mesna in tumour after mesna
administration was, however, not statistically significant and was
at least three-fold lower than the AUC value of mesna in plasma
after mesna administration. The high concentrations of mesna in
plasma after mesna were comparable with the high mesna
concentrations obtained in kidney after i.v. administration of
1000mgkg
 1 BNP7787. This dose of BNP7787 has been shown to
completely prevent cisplatin-induced nephrotoxicity in rats
(Hausheer et al, 1998), suggesting that the observed high
concentrations of mesna in kidney were capable of inactivating
(hydrated) cisplatin before the occurrence of toxicity. Since
mesna concentrations in plasma after mesna were comparable
to the high inactivating mesna concentrations in kidney after
BNP7787, this can likely explain why mesna administration
can reduce the antitumour activity of cisplatin. Controlled
pharmacokinetic studies of cisplatin in the presence or absence
of BNP7787 or mesna are necessary to provide the conclusive
evidence that mesna administration lowers the intact cisplatin
concentration by forming cisplatin-mesna adducts in plasma,
thereby reducing the antitumour activity, whereas BNP7787
administration does not.
BNP7787 administration has been shown to completely protect
the kidneys against cisplatin-induced toxicity in rats (Hausheer
et al, 1998). We measured high concentrations of BNP7787 and
mesna following administration of BNP7787 in kidney. The AUC of
mesna in kidney was approximately 4.5-fold higher than the value
in plasma, whereas the AUC of BNP7787 was grossly similar for the
two compartments. This finding is consistent with in vitro
observations that in plasma the reduction of BNP7787 into mesna
is very limited in contrast to the large reduction of BNP7787
observed in the cytosol fraction of the kidney cortex (Ormstad et al,
1983). The high kidney concentrations of BNP7787 and mesna are
in contrast to the low concentrations of both compounds observed
in skeletal muscle, liver, RBC and WARD tumour. These results
clearly indicate that the hydrophilic BNP7787 and its metabolite
mesna undergo negligible uptake by these tissues. The high
concentrations of BNP7787 and mesna in the kidney confirm our
hypothesis that the selectivity of BNP7787 in protecting the kidney
against cisplatin-induced toxicity (Hausheer et al, 1998; Boven
et al, 2002) is based on the preferential uptake of BNP7787 and its
local conversion into the thiol mesna in the kidney (Ormstad and
Uehara, 1982; Brock et al, 1984; Ormstad and Ohno, 1984). The
high local concentrations of mesna in the kidney can inactivate
(hydrated) cisplatin before the occurrence of toxicity by forming
nontoxic platinum complexes. In addition, mesna can protect the
kidney by acting as a scavenging agent for reactive oxygen species
(Bast et al, 1987; Mashiach et al, 2001), thereby preventing lipid
peroxidation which might be involved in cisplatin-induced
nephrotoxicity (Sadzuka et al, 1992). Further research should help
to further elucidate the precise mechanism of nephroprotection by
BNP7787.
Studies in rats showed that the dose of cisplatin could be safely
increased from 6 to 9mgkg
 1 when preceded by 750 or
1500mgkg
 1 BNP7787 i.v. (Hausheer et al, 1998). In nude mice,
however, weight loss increased when the dose of cisplatin
increased from 5 to 8mgkg
 1 in the presence of 1000mgkg
 1
BNP7787 (Boven et al, 2002). The pharmacokinetics of BNP7787
and mesna in the plasma of rats were compared with that in nude
mice (Boven et al, 2002) to find a possible explanation for the
difference in protection by BNP7787 between the two species. The
relative amounts of the metabolite mesna present in the circulation
plasma kidney liver RBC tumour
plasma kidney liver RBC tumour
B
N
P
7
7
8
7
 
A
U
C
 
(

m
o
l
 
m
i
n
 
m
l
−
1
 
o
r
 
g
)
0
50
100
150
200
250
*
*
M
e
s
n
a
 
A
U
C
 
(

m
o
l
 
m
i
n
 
m
l
−
1
 
o
r
 
g
)
0
200
400
600
800
1000
1200
*
*
*
A
B
Figure 4 AUC values of BNP7787 (A) and mesna (B) in the plasma,
kidney, liver, RBC and tumour from rats treated with 1000mg kg
 1 i.v.
BNP7787 (grey bars) compared to the values obtained after 1000mg kg
 1
i.v. mesna (white bars). All AUC values were determined from the
concentration–time curves shown in Figures 2 and 3 from 5min after drug
administration up to the time of the last measurable concentration or to
the last sampling time, that is, 150min. *Po0.01.
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safter BNP7787 administration seems to vary between the two
species. In nude mice, the AUC of mesna in plasma was
approximately 24% of the AUC of BNP7787 (Boven et al, 2002),
whereas in rats the AUC of mesna was approximately 50% of the
AUC of BNP7787. This suggests that, in contrast to rats, small
amounts of mesna are generated in nude mice. Furthermore, in
rats, the AUC
5 60 in plasma was approximately 5.2-fold higher for
mesna and 2.7-fold higher for BNP7787 than the AUC
5 60 values
measured in nude mice after an equivalent dose of 1000mgkg
 1
BNP7787. These results indicate that, in comparison to mice, the
administration of BNP7787 in rats results in higher concentrations
of BNP7787 and mesna in plasma, but most probably also in
kidney. This observation may partially explain the greater
protection by BNP7787 against cisplatin-induced toxicity in rats
than mice.
In conclusion, after BNP7787 administration high concentra-
tions of its metabolite mesna, which is more reactive with
(hydrated) cisplatin than its disulphide, were observed only in
the kidney. In contrast, after mesna administration, the reactive
thiol mesna was found in high concentrations in the kidney as well
as in plasma. The substantially higher concentrations of mesna in
plasma following mesna administration may explain why mesna
administration results in reduced antitumour activity of cisplatin
and why BNP7787 administration exerts no effect on antitumor
activity as reported previously (Hausheer et al, 1998; Boven et al,
2002). The pharmacokinetic results confirm the selective protec-
tion of the kidney by BNP7787, which makes BNP7787 a promising
chemoprotectant. In that respect, we have completed a phase I
study on BNP7787 preceding cisplatin in cancer patients,
demonstrating that BNP7787 was relatively nontoxic up to high
doses of 41gm
 2 (Verschraagen et al, in press). Furthermore, at
the higher dose levels of BNP7787 (18.4–41gm
 2), there appeared
to be no mutual pharmacokinetic interaction between BNP7787
and intact cisplatin, which was consistent with the observation that
several patients experienced objective tumor responses with
cisplatin preceded by BNP7787 administration (Verschraagen
et al, in press). BNP7787 is currently under investigation in three
randomised studies to determine its safety and efficacy as a
protective agent in combination with paclitaxel alone and in
combination with cisplatin plus paclitaxel.
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